Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ark Innovation ETF (NY: ARKK )

39.04 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ark Innovation ETF

3 Tech-Focused ETFs: Unleashing The Power Of Innovation
Taking a closer look at top-performing tech-focused ETFs like QQQ, XLK, and ARKK and unlocking the potential of innovation and diversification. 
Via MarketBeat
Topics ETFs
Will Cloudflare Go Back Into Rally Mode After Q2 Earnings Report?
Cloudflare shares are up 6% in the past three months, rebounding from a decline after its Q1 report. The company guided toward 650% EPS growth this year. 
Via MarketBeat
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
ARKK: The Pros and Cons Of Buying Into Cathie's Best-Known ETF
If you're a believer in the progress of science and technology and feel strongly that our best days are still ahead, then a slice of ARKK could be tempting. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. 
Via MarketBeat
Analysts Bullish On Exact Sciences' Advanced Cancer Screening
Exact Sciences sees a bump in stock price amid rising revenue and study results that show advancements to its flagship Cologuard colorectal screening product. 
Via MarketBeat
Twilio Up As Activist Investor Spurs Change, Cathie Wood Invests
Twilio stock surges on activist pressure and Cathie Wood's investment, as the company faces revenue challenges amid restructuring efforts to prioritize profit. 
Via MarketBeat
Topics ETFs
Forget Cathie Wood, Follow These 3 Hedge Fund Managers
The return and risk profiles of these three ‘hedgies’ are among the best in the business, making them well worth following. 
Via MarketBeat
Topics ETFs
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
MarketBeat Week in Review – 1/30 - 2/3
The markets are trending lower to end the week. It’s hard to figure out the markets after the blockbuster job report, but the MarketBeat team gave it a shot 
Via MarketBeat
Topics Artificial Intelligence Earnings Economy
Exposures Artificial Intelligence Financial Interest Rates
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
Can gains in Tesla, Zoom, Exact Sciences, and other growth stocks set the stage for Cathie Woods' Ark Innovation Fund to stage a comeback in 2023? 
Via MarketBeat
Topics ETFs
Cathie Wood Is Buying These Stocks, Should You?
Cathie Wood is known for her deep understanding of tech companies and for holding aggressive long positions in her tech funds. Let's look at what she's buying. 
Via MarketBeat
Topics ETFs
Zoom Video Continues to Work Through Normalization
Zoom Video (NASDAQ: ZM) has gone from an obscure but easy-to-use video communications platform to becoming a verb synonymous with video conferencing 
Via MarketBeat
Topics ETFs
Exposures COVID-19 Coal
Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
Unity Software has been on a wild ride after reporting better-than-expected earnings, but then rejecting a buyout offer by AppLovin. Is it ready to rally again? 
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.